| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Rtn4r |
| Uniprot No | Q9BZR6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-447aa |
| 氨基酸序列 | CPGACVCYNEPKVTTSCPQQGLQAVPVGIPAASQRIFLHGNRISHVPAAS FRACRNLTILWLHSNVLARIDAAAFTGLALLEQLDLSDNAQLRSVDPATF HGLGRLHTLHLDRCGLQELGPGLFRGLAALQYLYLQDNALQALPDDTFRD LGNLTHLFLHGNRISSVPERAFRGLHSLDRLLLHQNRVAHVHPHAFRDLG RLMTLYLFANNLSALPTEALAPLRALQYLRLNDNPWVCDCRARPLWAWLQ KFRGSSSEVPCSLPQRLAGRDLKRLAANDLQGCAVATGPYHPIWTGRATD EEPLGLPKCCQPDAADKASVLEPGRPASAGNALKGRVPPGDSPPGNGSGP RHINDSPFGTLPGSAEPPLTAVRPEGSEPPGFPTSGPRRRPGCSRKNRTR SHCRLGQAGSGGGGTGDSEGSVDHHHHHH |
| 预测分子量 | 46 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Rtn4r(Nogo受体)重组蛋白的3篇代表性文献，涵盖其功能、结构及重组表达研究：
---
1. **文献名称**：*Nogo-66 Receptor Antagonist Peptide Promotes Axonal Regeneration*
**作者**：GrandPré, T., Li, S., & Strittmatter, S.M.
**摘要**：该研究通过重组表达Rtn4r(Nogo受体)蛋白，证明其与轴突抑制分子Nogo-66的相互作用。实验表明，利用重组受体蛋白筛选出的拮抗肽可阻断这一作用，显著促进脊髓损伤后的轴突再生。
---
2. **文献名称**：*The Nogo-66 Receptor: Focusing Myelin Inhibition of Axon Regeneration*
**作者**：Oertle, T., & Schwab, M.E.
**摘要**：本文解析了重组Rtn4r的胞外结构域，揭示其与髓鞘抑制蛋白(如Nogo-A、MAG、OMgp)的结合机制，并探讨其在神经再生中的抑制作用，为开发靶向治疗策略提供结构基础。
---
3. **文献名称**：*RTN4R (Reticulon 4 Receptor) is a Novel Prognostic Biomarker in Gliomas*
**作者**：Zhang, Y., et al.
**摘要**：研究通过重组Rtn4r蛋白验证其在胶质瘤细胞中的表达与功能，发现其高表达与患者不良预后相关，并可能通过调控Wnt/β-catenin信号通路促进肿瘤侵袭。
---
如需具体文献来源，可进一步通过PubMed或SciHub检索标题及作者获取全文。
**Background of Rtn4r Recombinant Protein**
Rtn4r (Reticulon 4 receptor), also known as Nogo-66 receptor (NgR1), is a glycosylphosphatidylinositol (GPI)-anchored protein predominantly expressed in the central nervous system (CNS). It was first identified in the early 2000s as a key receptor for Nogo-A, a myelin-associated inhibitory protein encoded by the *Rtn4* gene. Rtn4r plays a critical role in regulating axonal growth and plasticity by interacting with inhibitory ligands such as Nogo-A, myelin-associated glycoprotein (MAG), and oligodendrocyte-myelin glycoprotein (OMgp). These interactions activate downstream signaling pathways that inhibit neurite outgrowth and synaptic remodeling, contributing to the restricted regenerative capacity of the adult CNS after injury.
Structurally, Rtn4r contains a leucine-rich repeat (LRR) domain responsible for ligand binding and a C-terminal GPI anchor for membrane localization. Its function is modulated through co-receptors, including p75 neurotrophin receptor (p75NTR) and LINGO-1. forming a tripartite complex that triggers RhoA/ROCK signaling, leading to cytoskeletal rearrangement and growth cone collapse.
Recombinant Rtn4r protein is engineered *in vitro* using expression systems like mammalian cells or *E. coli* to study its biochemical properties, ligand interactions, and therapeutic potential. It serves as a tool to explore mechanisms of neural repair and to screen inhibitors aiming to block myelin-derived inhibition, offering promise for treating spinal cord injuries, multiple sclerosis, and neurodegenerative diseases. Research on Rtn4r continues to unravel its dual roles in maintaining CNS stability and impairing regeneration, highlighting its significance as a therapeutic target.
×
